Stock listing
NASDAQ:FHTX Foghorn Therapeutics Inc. Stock
Home listing (NASDAQ) of Foghorn Therapeutics Inc.
Follow Foghorn Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:FHTX
$1.72 USD -0.07 (-3.9%)
Close on Nov 20, 2026
- Day range
- $1.66 – $1.80 USDNov 20, 2026
- Volume
- 919,929 sharesNov 20, 2026
- Market cap
- $103.1M USDAt the close on Nov 20, 2026 · price × 59.96M shares outstanding
- 52-week range
- $1.66 – $7.61 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.49M USDMedian day 529,113 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:FHTX · Home | $1.72 USD | -0.07 (-3.9%) | 919,929 | $1.74 | $1.80 | $1.66 | $1.79 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FHTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.72 | -0.07 | -3.9% | $1.74 | $1.80 | $1.66 | 919,929 | |
| $1.79 | -0.04 | -2.2% | $1.79 | $1.82 | $1.75 | 529,113 | |
| $1.83 | +0.04 | +2.2% | $1.81 | $1.85 | $1.73 | 1,762,228 | |
| $1.79 | -0.28 | -13.5% | $2.05 | $2.05 | $1.765 | 829,189 | |
| $2.07 | +0.02 | +1.0% | $2.04 | $2.08 | $1.94 | 534,219 | |
| $2.05 | -0.04 | -1.9% | $2.07 | $2.08 | $1.95 | 579,935 | |
| $2.09 | +0.19 | +10.0% | $1.95 | $2.10 | $1.883 | 761,430 | |
| $1.90 | -0.14 | -6.9% | $2.02 | $2.03 | $1.845 | 719,280 | |
| $2.04 | +0.17 | +9.1% | $2.08 | $2.12 | $1.89 | 1,393,839 | |
| $1.87 | -0.035 | -1.8% | $1.87 | $1.935 | $1.795 | 970,036 | |
| $1.905 | -0.195 | -9.3% | $2.10 | $2.10 | $1.80 | 1,008,456 | |
| $2.10 | -0.03 | -1.4% | $2.19 | $2.28 | $2.10 | 673,574 | |
| $2.13 | 0.00 | 0.0% | $2.15 | $2.21 | $2.08 | 624,747 | |
| $2.13 | +0.05 | +2.4% | $2.07 | $2.15 | $1.97 | 715,135 | |
| $2.08 | -0.01 | -0.5% | $2.08 | $2.09 | $2.005 | 555,607 | |
| $2.09 | -0.04 | -1.9% | $2.16 | $2.20 | $2.06 | 396,983 | |
| $2.13 | +0.08 | +3.9% | $2.04 | $2.13 | $2.03 | 483,346 | |
| $2.05 | 0.00 | 0.0% | $2.04 | $2.09 | $1.99 | 874,690 | |
| $2.05 | +0.05 | +2.5% | $1.99 | $2.06 | $1.93 | 509,734 | |
| $2.00 | -0.01 | -0.5% | $1.97 | $2.035 | $1.90 | 486,822 | |
| $2.01 | -0.03 | -1.5% | $2.00 | $2.09 | $1.985 | 301,051 | |
| $2.04 | +0.03 | +1.5% | $2.02 | $2.10 | $1.99 | 819,594 | |
| $2.01 | +0.14 | +7.5% | $1.87 | $2.065 | $1.87 | 555,099 | |
| $1.87 | +0.02 | +1.1% | $1.81 | $1.91 | $1.80 | 440,851 | |
| $1.85 | -0.04 | -2.1% | $1.81 | $1.90 | $1.81 | 981,304 | |
| $1.89 | +0.04 | +2.2% | $1.87 | $1.91 | $1.82 | 349,343 | |
| $1.85 | 0.00 | 0.0% | $1.85 | $1.89 | $1.80 | 1,071,894 | |
| $1.85 | -0.10 | -5.1% | $1.945 | $1.95 | $1.84 | 851,222 | |
| $1.95 | -0.05 | -2.5% | $1.98 | $2.00 | $1.94 | 586,299 | |
| $2.00 | +0.01 | +0.5% | $1.96 | $2.081 | $1.945 | 646,951 | |
| $1.99 | -0.10 | -4.8% | $2.05 | $2.14 | $1.885 | 1,228,058 | |
| $2.09 | +0.12 | +6.1% | $1.92 | $2.15 | $1.906 | 917,105 | |
| $1.97 | -0.03 | -1.5% | $2.00 | $2.02 | $1.835 | 984,692 | |
| $2.00 | -0.02 | -1.0% | $2.03 | $2.12 | $1.98 | 987,959 | |
| $2.02 | -0.90 | -30.8% | $2.91 | $2.91 | $1.99 | 2,546,614 | |
| $2.92 | -0.65 | -18.2% | $2.08 | $3.21 | $1.79 | 13,378,300 | |
| $3.57 | +0.05 | +1.4% | $3.55 | $3.60 | $3.50 | 419,958 | |
| $3.52 | 0.00 | 0.0% | $3.53 | $3.58 | $3.46 | 376,219 | |
| $3.52 | +0.02 | +0.6% | $3.49 | $3.62 | $3.40 | 337,374 | |
| $3.50 | -0.10 | -2.8% | $3.61 | $3.66 | $3.465 | 525,425 | |
| $3.60 | -0.27 | -7.0% | $3.83 | $3.85 | $3.55 | 518,520 | |
| $3.87 | -0.37 | -8.7% | $4.12 | $4.21 | $3.85 | 1,795,706 | |
| $4.24 | +0.09 | +2.2% | $4.21 | $4.32 | $4.15 | 328,885 | |
| $4.15 | +0.01 | +0.2% | $4.16 | $4.19 | $4.07 | 188,405 | |
| $4.14 | -0.06 | -1.4% | $4.21 | $4.25 | $4.07 | 502,030 | |
| $4.20 | +0.03 | +0.7% | $4.27 | $4.324 | $4.13 | 246,007 | |
| $4.17 | +0.05 | +1.2% | $4.17 | $4.23 | $4.08 | 354,921 | |
| $4.12 | -0.24 | -5.5% | $4.35 | $4.38 | $4.09 | 467,622 | |
| $4.36 | -0.06 | -1.4% | $4.415 | $4.56 | $4.33 | 399,648 | |
| $4.42 | -0.07 | -1.6% | $4.54 | $4.62 | $4.37 | 289,127 | |
| $4.49 | -0.18 | -3.9% | $4.65 | $4.65 | $4.46 | 396,829 | |
| $4.67 | -0.16 | -3.3% | $4.79 | $4.895 | $4.66 | 199,623 | |
| $4.83 | -0.09 | -1.8% | $4.81 | $4.91 | $4.66 | 219,642 | |
| $4.92 | +0.05 | +1.0% | $4.81 | $5.00 | $4.70 | 266,014 | |
| $4.87 | -0.30 | -5.8% | $5.16 | $5.21 | $4.84 | 442,157 | |
| $5.17 | -0.52 | -9.1% | $5.75 | $5.89 | $5.032 | 956,827 | |
| $5.69 | -0.05 | -0.9% | $5.63 | $5.76 | $5.45 | 218,800 | |
| $5.74 | -0.26 | -4.3% | $5.96 | $5.965 | $5.725 | 305,574 | |
| $6.00 | -0.22 | -3.5% | $6.17 | $6.24 | $5.96 | 370,707 | |
| $6.22 | -0.47 | -7.0% | $6.68 | $6.80 | $6.08 | 433,044 | |
| $6.69 | -0.16 | -2.3% | $6.85 | $6.85 | $6.51 | 318,860 | |
| $6.85 | -0.02 | -0.3% | $6.90 | $7.289 | $6.82 | 293,959 | |
| $6.87 | -0.20 | -2.8% | $7.35 | $7.35 | $6.57 | 402,922 | |
| $7.07 | +0.06 | +0.9% | $7.10 | $7.348 | $6.95 | 536,547 | |
| $7.01 | -0.05 | -0.7% | $6.93 | $7.61 | $6.89 | 1,326,593 |
- Ticker
- NASDAQ:FHTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
Latest deck · Nov 9, 2026
Investor Presentation (November 2026)
Investor deck · 37 slides
Latest news
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
Nov 9, 2026
Closed $2.04 (+9.1%) on Nov 9, 2026
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
Nov 3, 2026
Closed $2.13 (0.0%) on Nov 3, 2026
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Oct 1, 2026
Closed $2.92 (-18.2%) on Oct 1, 2026
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
Aug 6, 2026
Closed $5.57 (+14.1%) on Aug 6, 2026
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Jun 5, 2026
Closed $3.73 (-0.3%) on Jun 5, 2026
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
May 12, 2026
Closed $4.24 (-2.1%) on May 12, 2026
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 7, 2026
Closed $4.20 (-10.3%) on May 7, 2026
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Apr 21, 2026
Closed $5.39 (+2.3%) on Apr 22, 2026
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Mar 11, 2026
Closed $4.92 (-12.9%) on Mar 12, 2026
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Feb 23, 2026
Closed $5.75 (+0.3%) on Feb 23, 2026
Foghorn Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 30 in all · newest Nov 9, 2026 · oldest 2025
- Decks
- 54 decks · latest Nov 9, 2026
Where Foghorn Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:FHTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:FHTX | BOATS | United States | USD |
Valuation
EV/sales −0.1× against a median of 128×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$9.22M USD
- P/E
- 10.9×
- EV/sales
- −0.1×
- EV/EBITDA
- −2.5×
- Price/book
- Negative equity
- Gross margin
- Not reported
- Operating margin
- 2.1%
- Net margin
- 8.4%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.57
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. · NASDAQ:FHTX | US$103.1M | −US$9.22M | 10.9× | −0.1× | −2.5× | n/a | 8.4% | n/a | 1.57 |
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.72M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Cardiol Therapeutics Inc. Class A · TSX:CRDL | US$103.4M | US$83.06M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.45 |
| Heidelberg Pharma AG · XETR:HPHA | US$103.2M | US$81.75M | n/a | 8.0× | n/a | n/a | −320.9% | n/a | n/a |
| Vivani Medical, Inc. · NASDAQ:VANI | US$102.8M | US$88.24M | n/a | n/a | n/a | 7.8× | n/a | 0.0× | 0.93 |
| Paradigm Biopharmaceuticals Ltd. · ASX:PAR | US$101.6M | US$96.33M | n/a | 1,816× | n/a | 44.2× | n/a | 2.2× | n/a |
| Innate Pharma SA Class A · EURONEXT:IPH | US$101.5M | US$111.7M | n/a | 36.5× | n/a | n/a | n/a | n/a | n/a |
| BRIM Biotechnology, Inc. · TWSE:6885 | US$100.3M | US$70.71M | n/a | 220× | n/a | 2.1× | n/a | 0.0× | n/a |
| Minerva Neurosciences, Inc · NASDAQ:NERV | US$99.67M | US$22.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.68 |
| Median of the others | US$103.0M | US$83.89M | 128× | 5.4× | −258.3% | 0.0× | 1.49 |
Forecasts
5 strong buy · 5 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.88 · 6 analysts
- Revenue, year to Dec 2026
- 32.03M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Adrian Gottschalk | President & CEO |
| Ryan Maynard | Chief Financial Officer |
| Neil Gallagher | Most recently President, Head of Research & Development, Syndax Pharmaceuticals |
| Tom Lynch | President & Director, Fred Hutchinson Cancer Center |
| Michael LaCascia | Chief Legal Officer |
| Karin Hellsvik | Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations, Operations |
| Alena Reva | VP, Total Rewards & People Operations |
| Andrew Germain | VP, Legal |
| Dan Dinu | VP, Information Technology |
| Danette Daniels | VP, Protein Degrader Platform |
| Gromek Smolen | VP, Biology |
| Kevin Wilson | VP, Chemistry |
| Michael Garcia-Webb | VP, Program Executive, Chief of Staff Research |
| Saurabh Sewak | VP, New Products & Commercial Strategy |
| Alfonso Quintás-Cardama | Chief Medical Officer |
| Carlos Costa | Chief People Officer |
| Cigall Kadoch | Scientific Advisor to the Board of Directors; Founder, Foghorn Therapeutics |
| Doug Cole | Founder, Foghorn Therapeutics; Managing Partner, Flagship Pioneering |
| Gerald Crabtree | Founder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute |
| Lynne Parshall | Director, Ionis Pharmaceuticals |
| Michael Mendelsohn | Founder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals |
| Scott Biller | Executive Venture Partner, Google Ventures (GV) |
| Simba Gill | Executive Chairman, Serina Therapeutics and Sensorium Therapeutics |
| Steven Bellon | Chief Scientific Officer |
| Stuart Duty | Most recently served as Senior Managing Director at Guggenheim Securities, LLC |
Board
| Director | Role |
|---|---|
| Charles Sawyers | Investigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Canc |
| Simba Gill | Executive Chairman, Serina Therapeutics and Sensorium Therapeutics |
| Tom Lynch | President & Director, Fred Hutchinson Cancer Center |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +9.1% |
| Q2 2026 | Aug 6, 2026 · Before open | +14.1% |
| Q1 2026 | May 7, 2026 · Before open | −10.3% |
| Q4 2025 | Mar 5, 2026 | +1.9% |
| Q3 2025 | Nov 5, 2025 · Before open | +13.3% |
| Q2 2025 | Aug 5, 2025 · Before open | −2.7% |
| Q1 2025 | May 5, 2025 · Before open | −8.5% |
| Q4 2024 | Mar 6, 2025 · After close | +0.4% |
| Q3 2024 | Nov 4, 2024 · After close | +8.5% |
| Q2 2024 | Aug 8, 2024 · Before open | +4.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · Before open | −2.7% |
| Q4 2023 | Mar 7, 2024 · Before open | +0.6% |
| Q3 2023 | Nov 2, 2023 · Before open | +7.1% |
| Q2 2023 | Aug 4, 2023 · Before open | −0.5% |
| Q1 2023 | May 8, 2023 · Before open | −10.3% |
| Q4 2022 | Mar 9, 2023 · After close | +0.8% |
| Q3 2022 | Nov 8, 2022 · After close | −8.5% |
| Q2 2022 | Aug 9, 2022 · After close | +3.1% |
| Q1 2022 | May 9, 2022 · After close | −2.1% |
| Q4 2021 | Mar 10, 2022 · After close | +10.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 37 slides | Nov 9, 2026 |
| Investor Presentation (August 2026) | Investor deck | 64 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 64 slides | May 7, 2026 |
| Investor Presentation (April 2026) | Investor deck | 64 slides | Apr 21, 2026 |
| AACR 2026 | Conference | 14 slides | April 2026 |
| AACR April 2026 | Conference | 24 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 64 slides | Mar 11, 2026 |
| Investor Presentation (January 2026) | Investor deck | 63 slides | Jan 12, 2026 |
| Investor Presentation (November 2025) | Investor deck | 80 slides | Nov 7, 2025 |
| Investor Presentation (November 2025) | Investor deck | 75 slides | Nov 5, 2025 |
Show 50 decks
This page holds 50 of 54 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock, pre-funded warrants and series warrants Closed: US$50M raised · US$6.71 a share · Warrants at US$13.42 Buyers: BVF Partners; Deerfield Management; Flagship Pioneering (founding investor) Use of proceeds: Continued investment in the pipeline; extends cash runway into the first half of 2028 | Jan 13, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Oct 22, 2020.
- Price
- US$16.00 a share
- Shares offered
- 7,500,000 shares of common stock
- Offering size
- US$120 million
- Underwriters' option
- Up to 1,125,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Oct 27, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 28, 2020 |
| Filed publicly | Oct 2, 2020 |
| Amended twice | Newest Oct 22, 2020 |
| Shares registered with an exchange | Oct 19, 2020 |
| Declared effective by the SEC | Oct 22, 2020 |
| Final prospectus, with the price | Oct 23, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 26, 2020 |
| 424B4 · Prospectus | Oct 23, 2020 |
| EFFECT · Notice that a registration is effective | Oct 22, 2020 |
| CERT · Exchange's certificate of listing | Oct 22, 2020 |
| S-1/A · Registration statement, amended | Oct 22, 2020 |
| UPLOAD · Letter from the SEC | Oct 21, 2020 |
| CORRESP · Letter to the SEC | Oct 20, 2020 |
| CORRESP · Letter to the SEC | Oct 20, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 19, 2020 |
| S-1/A · Registration statement, amended | Oct 19, 2020 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 13, 2020 |
| CORRESP · Letter to the SEC | Oct 9, 2020 |
| UPLOAD · Letter from the SEC | Oct 8, 2020 |
| CORRESP · Letter to the SEC | Oct 2, 2020 |
| S-1 · Registration statement | Oct 2, 2020 |
| UPLOAD · Letter from the SEC | Sep 24, 2020 |
| DRS · Draft registration statement | Aug 28, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 23, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.9M | 22.6M | 34.2M | 19.2M | 1.32M | 430.0K | 0 | 0 |
| Cost of revenue | 3.33M | 3.12M | 109.7M | 19.2K | 7.51M | 57.7M | 1.79M | 379.0K |
| Gross profit | 27.6M | 22.6M | 34.2M | 19.2M | 1.32M | -57.3M | -1.79M | -379.0K |
| Research and development | 85.5M | 94.5M | 109.7M | 105.6M | 80.3M | 57.7M | 44.4M | 21.2M |
| Selling, general and administrative | 27.6M | 28.4M | 32.4M | 30.7M | 21.7M | 11.2M | 6.72M | 4.82M |
| Operating income | -86.4M | -102.7M | -107.9M | -117.1M | -100.7M | -68.5M | -51.1M | -26.0M |
| Depreciation and amortization | 3.33M | 3.12M | 3.45M | 3.32M | 3.23M | 1.33M | 693.0K | 379.0K |
| EBITDA | -83.1M | -99.6M | -104.5M | -113.8M | -97.5M | -67.2M | -50.4M | -25.7M |
| Interest expense | 11.6M | 1.91M | 979.0K | 540.0K | 371.0K | |||
| Income before tax | -74.3M | -86.6M | -94.2M | -108.9M | -101.3M | -68.8M | -51.1M | -26.3M |
| Income tax | 0 | 0 | 4.23M | 0 | 1.91M | 0 | 0 | 83.0K |
| Net income | -74.3M | -86.6M | -98.4M | -108.9M | -101.3M | -68.8M | -51.1M | -26.3M |
| Earnings per share, basic | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 | -6.23 | -12.20 | -1.34 |
| Earnings per share, diluted | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 | -6.23 | -12.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 80.9M | 55.5M | 80.3M | 52.2M | 101.1M | 92.8M | 15.0M | 40.0M |
| Short-term investments | 78.0M | 188.3M | 153.7M | 293.6M | 53.2M | 93.0M | ||
| Receivables | 2.38M | 300.0M | 842.0K | |||||
| Inventory | -353.2M | |||||||
| Current assets | 163.2M | 249.6M | 240.2M | 351.4M | 459.6M | 190.7M | 16.9M | 40.4M |
| Property, plant and equipment | 49.4M | 56.1M | 19.5M | 2.68M | 2.09M | |||
| Total assets | 198.1M | 284.0M | 285.9M | 404.9M | 519.8M | 255.6M | 22.3M | 43.1M |
| Accounts payable | 4.27M | 3.79M | 6.26M | 5.41M | 3.82M | 3.68M | 3.44M | 2.01M |
| Current liabilities | 59.7M | 67.0M | 58.4M | 55.2M | 48.7M | 18.8M | 12.7M | 3.46M |
| Long-term debt | 0 | 19.7M | 11.0M | 7.03M | ||||
| Total debt | 41.3M | 37.1M | 45.1M | 51.5M | 0 | 19.7M | 15.1M | 7.03M |
| Total liabilities | 306.6M | 329.5M | 363.1M | 404.8M | 422.9M | 109.4M | 23.8M | 82.3M |
| Shareholders' equity | -108.5M | -45.5M | -77.2M | 112.0K | 96.9M | 146.2M | -88.0M | -39.3M |
| Shares outstanding | 56.7M | 55.6M | 42.3M | 41.8M | 41.3M | 36.8M | 4.87M | 19.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -86.1M | -100.4M | -118.1M | 193.6M | -50.3M | -31.3M | -46.3M | -22.6M |
| Capital spending | -50.0K | -906.0K | -1.22M | -1.21M | -3.31M | -16.2M | -968.0K | -1.54M |
| Free cash flow | -86.1M | -101.3M | -119.3M | 192.4M | -53.6M | -47.5M | -47.3M | -24.2M |
| Cash from investing | 112.0M | -29.9M | 144.4M | -244.3M | 36.2M | -108.9M | -964.0K | -1.54M |
| Cash from financing | 1.02M | 105.4M | 1.78M | 1.76M | 22.4M | 217.5M | 24.0M | 51.8M |
| Share buybacks | 1.76M | 43.6M | 123.3M | |||||
| Change in cash | 27.0M | -24.9M | 28.1M | -48.9M | 8.34M | 77.3M | -23.3M | 27.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 13, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jan 12, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 8-K · Current report | Dec 4, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 8-K · Current report | Jul 1, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | May 5, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 5, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 5, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 1, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 424B5 · Prospectus | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Feb 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Jan 24, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jan 24, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 24, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 4, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Results | SEC |
| 8-K · Current report | Oct 10, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Sep 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 4, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Aug 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | May 30, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 24, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 8-K · Current report | May 22, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 20, 2024 | Offer document | SEC |
| 8-K · Current report | May 20, 2024 | Current report | SEC |
| 8-K · Current report | May 6, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 6, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | May 6, 2024 | Offer document | SEC |
| 8-K · Current report | May 6, 2024 | Results | SEC |
| ARS · Annual report to shareholders | May 3, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 3, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 3, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2024 | Management or board change | SEC |
| 8-K · Current report | Apr 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 7, 2024 | Results | SEC |
| 10-K · Annual report | Mar 7, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 17, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 8-K · Current report | Jan 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 4 · Change in ownership | Sep 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 13, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2023 | Current report | SEC |
| 8-K · Current report | Aug 31, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 16, 2023 | Other filings | SEC |
| 8-K · Current report | Aug 10, 2023 | Current report | SEC |
| 8-K · Current report | Aug 8, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 4, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2023 | Results | SEC |
| 8-K · Current report | Jun 28, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 22, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Jun 5, 2023 | Current report | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 8, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 9, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2023 | Results | SEC |
| 8-K · Current report | Mar 8, 2023 | Current report | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
This page holds 200 of 356 filings. Open Filings
Cap table
Built by 6ix from Foghorn Therapeutics Inc.’s releases · as of Oct 30, 2026
- Common shares
- 59,962,650
- Fully diluted
- 59,962,650
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 59,962,650 | Oct 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$13.42 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 59,962,650 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ian Smith Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Stoke Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Sep 19, 2023); Solid Biosciences Inc. (Chairman of the Board · Since at least Dec 10, 2020) | Director · Since at least Apr 27, 2021 |
| Kristian Humer Other companies: 4D Molecular Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 9, 2025); Sensei Biotherapeutics, Inc. (Director · Jul 30, 2021 – May 21, 2025 · Past); Viridian Therapeutics, Inc. (CFO and CBO · Jul 26, 2021 – Feb 8, 2023 · Past) | Chief Financial Officer · Since at least Apr 16, 2024 |
| Ryan Maynard Other companies: Iovance Biotherapeutics, Inc. (Director · Since at least Feb 16, 2015); Tvardi Therapeutics, Inc. (CHIEF FINANCIAL OFFICER · Sep 12, 2022 – Feb 8, 2024 · Past); Rigel Pharmaceuticals, Inc. (EVP & CFO · May 27, 2010 – Nov 3, 2017 · Past) | Chief Financial Officer · Since at least Feb 23, 2026 |
| Stuart Duty Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Jul 15, 2024); EyePoint, Inc. (Board Member · Since at least Oct 16, 2023); Achieve Life Sciences, Inc. (Director · Since at least Mar 29, 2023) | Director · Since at least May 1, 2025 |
| Jose Baselga Other companies: Bristol-Myers Squibb Company (Director · Mar 1, 2018 – Sep 30, 2018 · Past); Varian Medical Systems Inc (Director · Mar 1, 2017 – Feb 9, 2018 · Past) | Director · Oct 22, 2020 – Oct 22, 2020 · Past |
| Neil Gallagher Other companies: Zymeworks Inc. (Director · Apr 2, 2024 – Dec 10, 2024 · Past); Syndax Pharmaceuticals, Inc. (President, Head of R&D · Feb 7, 2024 – Feb 10, 2025 · Past) | Most recently President, Head of Research & Development, Syndax Pharmaceuticals · Since at least May 1, 2025 |
| Thomas J Lynch Jr Other companies: Natera, Inc. (Director · Since at least Jun 2, 2026); Bristol-Myers Squibb Company (EVP & Chief Scientific Officer · Dec 12, 2017 – Apr 3, 2019 · Past) | Director · Since at least Oct 27, 2022 |
| Allan Reine Other companies: Prime Medicine, Inc. (Chief Executive Officer, Director · Since at least Jan 17, 2024) | Chief Financial Officer · Jan 26, 2023 – Jan 16, 2024 · Past |
| David Schenkein Other companies: Prime Medicine, Inc. (Board Member · Since at least Nov 4, 2026) | General Partner, Co-leader, Agios · Until Apr 13, 2026 · Past |
| Michael Mendelsohn Other companies: Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Jun 14, 2022 · Past) | Founder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals · Since at least Oct 22, 2020 |
All 34 people
| Person | Seat |
|---|---|
| Samuel Agresta Other companies: OnKure Therapeutics, Inc. (Chief Medical Officer · Since at least Oct 4, 2024) | Chief Medical Officer · Oct 22, 2020 – Sep 11, 2023 · Past |
| Adrian Gottschalk | President & CEO · Since at least Apr 13, 2026 |
| Alena Reva | VP, Total Rewards & People Operations · Since at least Nov 5, 2026 |
| Alfonso Quintás-Cardama | Chief Medical Officer · Since at least Nov 5, 2026 |
| Andrew Germain | VP, Legal · Since at least Nov 5, 2026 |
| Anna Rivkin | Chief Business Officer · Since at least Sep 3, 2024 |
| Carlos Costa | Chief People Officer · Since at least Jan 24, 2024 |
| Charles Sawyers | Investigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Canc · Since at least Nov 5, 2026 |
| Cigall Kadoch | Scientific Advisor to the Board of Directors; Founder, Foghorn Therapeutics · Since at least Oct 22, 2020 |
| Dan Dinu | VP, Information Technology · Since at least Nov 4, 2026 |
| Danette Daniels | VP, Protein Degrader Platform · Since at least Apr 9, 2026 |
| Doug Cole | Founder, Foghorn Therapeutics; Managing Partner, Flagship Pioneering · Since at least Nov 4, 2026 |
| Gerald Crabtree | Founder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute · Since at least Nov 5, 2026 |
| Gromek Smolen | VP, Biology · Since at least Apr 9, 2026 |
| Karin Hellsvik | Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations, Operations · Since at least Nov 3, 2026 |
| Kevin Wilson | VP, Chemistry · Since at least Nov 5, 2026 |
| Lynne Parshall | Director, Ionis Pharmaceuticals · Since at least Nov 5, 2026 |
| Michael Garcia-Webb | VP, Program Executive, Chief of Staff Research · Since at least Nov 5, 2026 |
| Michael LaCascia | Chief Legal Officer · Since at least Nov 9, 2020 |
| Saurabh Sewak | VP, New Products & Commercial Strategy · Since at least Nov 5, 2026 |
| Scott Biller | Executive Venture Partner, Google Ventures (GV) · Since at least Nov 5, 2026 |
| Simba Gill | Executive Chairman, Serina Therapeutics and Sensorium Therapeutics · Since at least Nov 5, 2026 |
| Steven Bellon | Chief Scientific Officer · Since at least Apr 9, 2026 |
| Tom Lynch | President & Director, Fred Hutchinson Cancer Center · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Foghorn Therapeutics Inc.